health research institute (hri)

Making the invisible visible

Full Spectrum Molecular Analysis

Chemical Residue Testing

Tested Clean

Molecular Diagnostics

Research & Development

Custom R&D and Quality Assurance Solutions

Our mission, creating change.

Create transparency through testing

Empower consumers to make intelligent decisions about their health.

Market-demand drives change of the food system

How can hri help you, looking for answers.

" * " indicates required fields

Copyright 2024 Health Research Institute

National Institutes of Health, Ministry of National Health Services, Regulations and Coordination

Government of Pakistan

Health Research Institute (HRI)

CALL FOR RESEARCH PROPOSALS ROUND - 4

Date Extended Untill 15th January 2024

Health Research Institute (HRI) is pleased to advertise the 4th round of “call for proposals” to promote implementation and Health Systems Research across the Country in line with its mandate.

Executive Director

News & Events

Dr. Nighat Murad

How To Create a Website

National Cancer Registry of Pakistan: First Comprehensive Report of Cancer Statistics 2015-2019

We are proudly sharing that Health Research Institute (National Institute of Health) has been certified for ISO 9001:2015 for its systems quality

COVID-19 UPDATES

HRI at Glance

Key National

Pakistan Journal of Medical Research

HRI as a Focal Person

Ministry of National Health Services, Regulation and Coordination (NHSRC) has nominated Dr Huma Quresh ...

Rabies is endemic in Pakistan, with human infections being mostly due to the dog bite and cases are mostly diagnosed on clinical grounds ...

National Bioethics Committee (NBC) is the major, official body to uphold the bioethical principles in all sectors of health-care in the country.

Globally cancer remains the most dreadful disease, and the rising incidence of different types of cancer has been attributed to radiation ...

Related Links

Cabinet Approved MAP of Pakistan

ministry of NHSRC

RABIES CONTROL PROGRAM

MALARIA CONTROL PROGRAMME

World health orgnization

Health Services Academy

Pakistan Journal of Medical Research (PJMR)

national Bioethics committee

MEDIA & AWARENESS CAMPAIGNS

National cancer registration programme

national AIDS Control programme

Shahrah-e-Jamhuriat, G-5/2

Islamabad, Pakistan

Tel: 00-92-51-9216793, 00-92-51-9207386

Fax: 00-92-51-9216774

• Healthcare Services
• Find a Doctor
• Patient Portal
• Research and Education

Your recent searches

• Find a Location
• Nursing Careers
• Physical Therapy Careers
• Medical Education
• Research & Innovation
• Pay My Bill
• Billing & Insurance Questions
• For Healthcare Professionals
• News & Publications
• Classes & Events
• Philanthropy

MedStar Health Research Institute

• Clinical Trials
• Principal Investigators
• Research Networks
• Research Support
• Scientific Services

About MedStar Health Research Institute

• Contact MedStar Health Research Institute

Browse this page

From bench to bedside to community

Situated at the crossroads of academics and real-world healthcare environments, the MedStar Health Research Institute (MHRI) creates new knowledge that provides the latest advances for patients at nearly 300 sites of care in the region. Our researchers cover many areas and types of research, across the six comprehensive research networks aligned with our clinical and operational service lines, advancing the health of our patients today and tomorrow. 

Our research teams work collaboratively to understand the needs of our clinicians and patients, with the goal of developing more effective and safe ways to treat people and meet these needs. Our goal is to conduct applied research and implementation science, grounded in theory, to advance safety, efficiency, and quality for our clinicians and patients. 

MedStar Health Research Institute advances the health and wellbeing of all people through transformational, interdisciplinary, and inclusive research.

Founded in 1963,the MedStar Health Research Institute  is the research division of MedStar Health. We provide scientific, administrative, and regulatory support for clinical research throughout the MedStar Health system. 

As the research arm  of the MedStar Health academic healthcare system, our contribution to the healing work performed across the region and in the communities we serve is led by our commitment to advance health. Led by Dr. Neil Weissman, the Institute supports more than 1,000 associates dedicated to advancing health through research across the region at more than 40 MedStar Health sites.

Programs and services

Clinical trials

While we continue to enhance treatment regimens, ongoing clinical research is the way to best improve patient health and welfare—now and in the future. Every day, our investigators are leading a variety of clinical trials, testing new treatment options, and finding new ways to provide supportive care and symptom management. As a result, novel discoveries and breakthrough innovations benefit our patients more immediately and allow us to deliver the highest quality of care with the best possible outcomes. By participating in a clinical study at MedStar Health, you can not only play an active role in your own healthcare, but possibly help others in the future.

Research networks

Wherever you look throughout the our health system, you're likely to find highly qualified scientists and investigators conducting leading edge clinical research. MedStar Health Research Institute researchers cover many areas and types of research across the six comprehensive networks: Cardiovascular, Healthcare Delivery, Cancer, Medical and Surgical, Orthopedics & Sports Medicine, and NeuroScience and Rehabilitation.

Scientific core services

Our Research Institute's Multidisciplinary Core Services function to support investigators as an interdisciplinary resource. Investigators are encouraged to work with their respective Scientific Center Administrator to access each of the cores. These services include Biostatistics and Biomedical Informatics, Biochemistry and Biomarker Core, Penn Medical Laboratory, Pre-Clinical Research Laboratory, and Research Pharmacy.

Our blog posts

Research resources.

No matter your involvement in research throughout MedStar Health Research Institute and the MedStar Health system, here you will find resources and information to keep you informed and educated.

Our leadership

We are dedicated to supporting the academic platform of MedStar Health by conducting high quality translational and health sciences research throughout our health system.

The Board of Directors is supported by a leadership team that encompasses all areas of research. The leadership team is supported by the advisory board, which includes representatives from many of the facets of research being completed at MedStar Health.

How Rochester medical research events will help you discover your ancestry, health risks

A series of federal medical research events in Rochester are seeking people willing to share their health story and information to aid the push to reduce health inequality in New York and across the country.

The National Institutes of Health’s All of Us Journey — a traveling, hands-on exhibit that raises awareness about the All of Us Research Program — will be held this month at Ibero American Action League Inc, International Plaza and University of Rochester Medical Center.

The stakes of improving diversity in medical research are crystal clear in the Rochester area, where people of color and those living in poor neighborhoods are suffering the steepest drops in life expectancy in recent years .

Why consider participating in All of Us?

At first, Michelle Anderson, a retired nurse, who is Black, was very skeptical when she first heard about the All of Us program events near her Massachusetts home in 2022, USA TODAY Network reported .

"I had flashbacks of stories and history and all those things the average African American thinks about when you mention research," she said, referring to the nation’s history of racism and abuses in medical experimentation.

Health inequality in NY: Life expectancy has fallen steeply for people in the Finger Lakes region: Here's why

What changed Anderson’s mind was learning about the program’s privacy protections, as well as the sense of empowerment it provided by giving her a role in helping to shape the push for health equality.

Anderson’s program results, including genetic testing, also confirmed her body metabolizes medicines more slowly than average, which allowed her to participate more proactively in her own health care treatment.

New York politics: NY approved a $37B Medicaid budget. Where is money going, how will it impact health care?

Where are All of Us events in Rochester?

The program events in Rochester have been set to run through May 24.

The event today is at University of Rochester Medical Center, 265 Crittenden Blvd., behind Saunders Research Building. There are also events May 21 through May 24 at Trillium Health, 259 Monroe Ave. All these events run from 10 a.m. to 4 p.m.

These events include an opportunity for visitors to sign up to participate in the program.

If you join  All of Us  and provide biosamples, like blood or saliva, you may choose to  learn more about your DNA , including:

• Your genetic ancestry
• Your risk for certain  hereditary diseases
• Your  body's reaction to certain medicines

There is no cost to participate other than some of your time. Most people will spend no more than a few hours a year taking part in the program's activities, the program website noted.

Health care crises: Mental health care needs spiked 23% in NY as treatment capacity dropped 10%

What is the All of Us Research Program?

The research program has a goal of collecting medical data on 1 million Americans to better understand the nation's diversity. Among the first 500,000 participants, more than 60,000 had Hispanic ancestry, which is about four-times more than any previous study at the time in 2022.

Prior genetic studies have largely included people of European ancestry, but findings might be different for people from other backgrounds.

About half the All of Us participants who had their genes sequenced as of 2022 identified as belonging to a racial or ethnic minority and even more are either low-income, have a disability, live in a rural location or are otherwise historically underrepresented in research.

"The fundamental driver of the program is diversity," said Dr. Josh Denny, chief executive officer of the All of Us Research Program.

What kind of information can people learn by participating?

Like the for-profit genetic information systems, All of Us lets participants know what their genes show about their ancestry. Other information returned to participants includes data on lactose intolerance and other food-related findings.

Only about 3% to 5% of participants will learn that they have a high risk for 59 genetic diseases like the BRCA1 and BRCA2 genes that predispose women for breast and ovarian cancers and men for breast and prostate tumors.

All 59 are "actionable," meaning someone can do something to reduce their risk of disease if they are found to have one of these mutations.

To learn more about the All of Us Research Program, visit JoinAllofUs.org/tour

Karen Weintraub of USA TODAY contributed to this report

• Share full article

Advertisement

Supported by

U.S. Suspends Funding for Group at Center of Covid Origins Fight

The decision came after a scorching hearing in which lawmakers barraged EcoHealth Alliance’s president with claims of misrepresenting work with Chinese virologists.

By Benjamin Mueller

The Biden administration, under acute pressure from House lawmakers, moved on Wednesday to ban funding for a prominent virus-hunting nonprofit group whose work with Chinese scientists had put it at the heart of theories that Covid leaked from a lab.

The decision, announced in a letter from the Department of Health and Human Services, came on the heels of a scorching congressional hearing this month at which lawmakers barraged the group’s president with suggestions that he had misrepresented work with virologists in Wuhan, China, where the pandemic began. Republicans went further, demanding that Peter Daszak, the president of the nonprofit, EcoHealth Alliance, be criminally investigated.

For EcoHealth, which relied on federal funding to study the threat of wild animal viruses, the loss of funding is another twist in a saga that has long dominated discussions of how the pandemic began.

In April 2020, under orders from the Trump administration, the National Institutes of Health terminated a grant to EcoHealth amid President Donald J. Trump’s feud with China over the origin of the coronavirus. Three years later, an internal federal watchdog agency determined that the N.I.H. had failed to give a proper cause for ending the grant, which supplied an average of roughly $625,000 per year. The N.I.H. restarted a pared-back version of the award.

Now, with Republicans stepping up their campaign against EcoHealth, and Democrats joining in the anger, the Biden administration has cut off funding for EcoHealth again.

Health officials said they were suspending three active N.I.H. grants to EcoHealth that totaled $2.6 million for last year. And they proposed barring the group from receiving future federal research funding. Such bans, they said, usually last no more than three years, but could be longer or shorter.

In explaining the decision, health officials cited a series of lapses that the N.I.H. had first reported nearly three years ago . Chief among them was EcoHealth’s failure to promptly report findings from studies on how well bat coronaviruses grow in mice, health officials said.

“I have determined that the immediate suspension of EHA is necessary to protect the public interest,” wrote Henrietta K. Brisbon, a health department official, referring to EcoHealth Alliance.

She cited problems in EcoHealth’s monitoring of work done at the Wuhan Institute of Virology, where some of EcoHealth’s grant money was apportioned; the late submission of a progress report; and the possibility that a risky experiment had violated the terms of a grant.

EcoHealth said that it would contest the proposal to bar it from federal funding.

“We disagree strongly with the decision and will present evidence to refute each of these allegations and to show that N.I.H.’s continued support of EcoHealth Alliance is in the public interest,” the nonprofit said in a statement.

EcoHealth has also faced suspicion over a federal grant proposal that it made in 2018 to team up with the same Wuhan virology lab on coronavirus experiments that Republicans believe could have led to the pandemic, despite that project’s never receiving funding.

But for all the scrutiny of EcoHealth, there remains no evidence linking it directly with the beginning of the pandemic.

Federal health officials have said repeatedly that the viruses being studied with taxpayer funding at the Wuhan lab bore no resemblance to the one that set off the coronavirus outbreak, making it impossible that they had been responsible for the public health crisis.

Many scientists, including some whose criticisms of EcoHealth have been cited by House lawmakers in recent weeks, say that early cases and viral genomes point to a different origin for the pandemic: an illegal wild-animal market in Wuhan. Samples collected from the market were revealed last year to contain genetic material from the coronavirus and from animals like raccoon dogs, a scenario that scientists have said is consistent with a market origin.

Representative Brad Wenstrup of Ohio, a Republican who serves as the chairman of the Select Subcommittee on the Coronavirus Pandemic, which held the hearing this month, celebrated the suspension of EcoHealth’s funding. He called it “not only a victory for the U.S. taxpayer, but also for American national security and the safety of citizens worldwide.”

Representative Raul Ruiz of California, the subcommittee’s top Democrat, also welcomed the decision, describing EcoHealth’s conduct as “a departure from the longstanding legacy of good faith partnerships between the N.I.H. and federal grantees.”

Last year, the Biden administration barred the Wuhan Institute of Virology from receiving federal funding for a period of 10 years.

The health department said in a statement that EcoHealth had not complied with federal regulations, necessitating that it, too, now be barred. But the health department did not respond to questions about the timing of that decision, nearly three years after most of the facts cited in its assessment were released by health officials.

Benjamin Mueller reports on health and medicine. He was previously a U.K. correspondent in London and a police reporter in New York. More about Benjamin Mueller

Funding Opportunities

Rfa #cch-2024-01 – communities mobilizing for safety: a public health approach to sexual violence prevention.

Applications Due: May 24, 2024, by 5:00 PM EST

RFP #23-0010 YGetit? GET! Mobile Application

Proposals Due: April 23, 2024, at4:00 PM ET

RFA #23-0005 Ryan White Part B HIV/AIDS Support Services to Address Social Determinants of Health

Applications Due: April 10, 2024, by 4:00 PM ET

RFP #23-0009 YGetit? Tested Animation

Proposals Due: April 5, 2024, at 4:00 PM ET

National Quality Improvement Consultant

Due date: February 16, 2024

SOI #23-0013 Hepatitis C (HCV) Learning Collaborative for Substance Use Disorder (SUD) Treatment Programs

Due Date: February 27, 2024, by 4:00 PM ET

Request for Bids – Increasing Colorectal Cancer Screening in Federally Qualified Health Centers

Bids due: November 16, 2023

READ THIS AGREEMENT CAREFULLY BEFORE YOU CLICK THE “I AGREE TO THE LICENSE TERMS” BUTTON. BY CLICKING ON THE “I AGREE TO THE LICENSE TERMS” BUTTON, THE PERSON ACCEPTING THIS AGREEMENT ACKNOWLEDGES THAT (1) HE OR SHE IS AUTHORIZED TO ENTER INTO THIS AGREEMENT FOR AND ON BEHALF OF YOU, AND IS DOING SO, AND (2) HE OR SHE HAS READ, UNDERSTANDS AND AGREES THAT YOU SHALL BE BOUND BY THESE TERMS AND CONDITIONS AND ALL MODIFICATIONS AND ADDITIONS PROVIDED FOR. IF YOU DO NOT AGREE WITH THESE TERMS AND CONDITIONS, CLICK ON THE “RETURN” BUTTON AND INSTALLATION WILL TERMINATE. IF YOU ARE NOT AUTHORIZED TO ENTER INTO AND BIND YOUR INSTITUTION TO THIS AGREEMENT, CLICK ON THE “I AM NOT THE AUTHORIZED SIGNATORY” BUTTON.

I AGREE TO THE LICENSE TERMS (Click to agree and on following screen click Code->Download Zip to download 13MB File)

I DO NOT AGREE TO THE LICENSE TERMS (you must agree to the licensing terms to access the Sfold Download)

HEALTH Research Institute

Onyebuchi Ononogbu

• HEALTH-RCMI Affiliates

Onyebuchi J. Ononogbu is a dynamic and driven individual with a strong dedication to advancing pharmacy practice and improving patient outcomes. Currently serving as a Research Assistant Professor in the Department of Pharmacy Practice and Translational Research and a Hematology/Oncology Clinical Pharmacy Specialist at Harris Health System Research, Ononogbu's expertise lies in cancer health disparities, quality improvement, and diversity/equity inclusion within healthcare.

Her educational journey has been marked by excellence, culminating in the attainment of a Doctor of Pharmacy degree from the University of the Incarnate Word Feik School of Pharmacy in San Antonio, TX, where she graduated Cum Laude. Prior to this, she completed her Bachelor of Science in Allied Health and Diagnostic Sciences at the University of Connecticut, Storrs, CT.

Ononogbu's commitment to advancing pharmacy practice is evident through her research contributions, including publications in prestigious journals such as Clinical Lymphoma, Myeloma and Leukemia, and presentations at various conferences. Her work focuses on critical issues such as adherence to oral endocrine therapy, clinical outcomes in acute lymphoblastic leukemia, and optimizing chemotherapy administration processes.

In addition to her academic and research pursuits, Ononogbu is actively involved in professional organizations such as the Hematology Oncology Pharmacy Association and the American Society of Health-System Pharmacists. She also co-founded the Pharmacy Initiative Leaders (PILs), demonstrating her leadership skills and commitment to fostering innovation in pharmacy practice.

Ononogbu's contributions have been recognized through numerous awards and honors, including the Patient Advocate Award from the American College of Clinical Pharmacy Hematology/Oncology Practice and Research Network. Her passion for improving patient care and advancing the pharmacy profession underscores her role as a leader and innovator in the field.

Research Areas

• Access to Care
• Racism and Discrimination